Adjuvant therapy in the elderly: Making the right decision

Hyman B. Muss, Laura Biganzoli, Daniel J. Sargent, Matti Aapro

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Adjuvant chemotherapy has led to improvements in relapse-free and overall survival in patients with breast, colon, and non-small-cell lung cancer, yet many older patients are not offered these potentially life-saving treatments. Moreover, older patients have been either excluded or under-represented in most adjuvant trials, limiting the generalizability of these treatments to older populations. Limited data in elders suggest that older patients derive significant benefits from adjuvant therapies provided they have life expectancies exceeding 5 years. Making treatment decisions in elders is challenging. Many have major comorbidities that may substantially limit life expectancy and minimize or negate the benefits of adjuvant chemotherapy. In this review, we discuss the potential benefits of adjuvant treatment in older patients with solid tumors with a focus on general principles involved in the selection of adjuvant therapy for patients with breast, colon, and non-small-cell lung cancer. In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer.

Original languageEnglish (US)
Pages (from-to)1870-1875
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number14
DOIs
StatePublished - May 10 2007
Externally publishedYes

Fingerprint

Decision Making
Adjuvant Chemotherapy
Life Expectancy
Non-Small Cell Lung Carcinoma
Therapeutics
Comorbidity
Colon
Breast
Neoplasms
Recurrence
Survival
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Muss, H. B., Biganzoli, L., Sargent, D. J., & Aapro, M. (2007). Adjuvant therapy in the elderly: Making the right decision. Journal of Clinical Oncology, 25(14), 1870-1875. https://doi.org/10.1200/JCO.2006.10.3457

Adjuvant therapy in the elderly : Making the right decision. / Muss, Hyman B.; Biganzoli, Laura; Sargent, Daniel J.; Aapro, Matti.

In: Journal of Clinical Oncology, Vol. 25, No. 14, 10.05.2007, p. 1870-1875.

Research output: Contribution to journalArticle

Muss, HB, Biganzoli, L, Sargent, DJ & Aapro, M 2007, 'Adjuvant therapy in the elderly: Making the right decision', Journal of Clinical Oncology, vol. 25, no. 14, pp. 1870-1875. https://doi.org/10.1200/JCO.2006.10.3457
Muss, Hyman B. ; Biganzoli, Laura ; Sargent, Daniel J. ; Aapro, Matti. / Adjuvant therapy in the elderly : Making the right decision. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 14. pp. 1870-1875.
@article{87605da7a043404f87a330307e92e0a0,
title = "Adjuvant therapy in the elderly: Making the right decision",
abstract = "Adjuvant chemotherapy has led to improvements in relapse-free and overall survival in patients with breast, colon, and non-small-cell lung cancer, yet many older patients are not offered these potentially life-saving treatments. Moreover, older patients have been either excluded or under-represented in most adjuvant trials, limiting the generalizability of these treatments to older populations. Limited data in elders suggest that older patients derive significant benefits from adjuvant therapies provided they have life expectancies exceeding 5 years. Making treatment decisions in elders is challenging. Many have major comorbidities that may substantially limit life expectancy and minimize or negate the benefits of adjuvant chemotherapy. In this review, we discuss the potential benefits of adjuvant treatment in older patients with solid tumors with a focus on general principles involved in the selection of adjuvant therapy for patients with breast, colon, and non-small-cell lung cancer. In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer.",
author = "Muss, {Hyman B.} and Laura Biganzoli and Sargent, {Daniel J.} and Matti Aapro",
year = "2007",
month = "5",
day = "10",
doi = "10.1200/JCO.2006.10.3457",
language = "English (US)",
volume = "25",
pages = "1870--1875",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Adjuvant therapy in the elderly

T2 - Making the right decision

AU - Muss, Hyman B.

AU - Biganzoli, Laura

AU - Sargent, Daniel J.

AU - Aapro, Matti

PY - 2007/5/10

Y1 - 2007/5/10

N2 - Adjuvant chemotherapy has led to improvements in relapse-free and overall survival in patients with breast, colon, and non-small-cell lung cancer, yet many older patients are not offered these potentially life-saving treatments. Moreover, older patients have been either excluded or under-represented in most adjuvant trials, limiting the generalizability of these treatments to older populations. Limited data in elders suggest that older patients derive significant benefits from adjuvant therapies provided they have life expectancies exceeding 5 years. Making treatment decisions in elders is challenging. Many have major comorbidities that may substantially limit life expectancy and minimize or negate the benefits of adjuvant chemotherapy. In this review, we discuss the potential benefits of adjuvant treatment in older patients with solid tumors with a focus on general principles involved in the selection of adjuvant therapy for patients with breast, colon, and non-small-cell lung cancer. In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer.

AB - Adjuvant chemotherapy has led to improvements in relapse-free and overall survival in patients with breast, colon, and non-small-cell lung cancer, yet many older patients are not offered these potentially life-saving treatments. Moreover, older patients have been either excluded or under-represented in most adjuvant trials, limiting the generalizability of these treatments to older populations. Limited data in elders suggest that older patients derive significant benefits from adjuvant therapies provided they have life expectancies exceeding 5 years. Making treatment decisions in elders is challenging. Many have major comorbidities that may substantially limit life expectancy and minimize or negate the benefits of adjuvant chemotherapy. In this review, we discuss the potential benefits of adjuvant treatment in older patients with solid tumors with a focus on general principles involved in the selection of adjuvant therapy for patients with breast, colon, and non-small-cell lung cancer. In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer.

UR - http://www.scopus.com/inward/record.url?scp=34249826935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249826935&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.10.3457

DO - 10.1200/JCO.2006.10.3457

M3 - Article

C2 - 17488985

AN - SCOPUS:34249826935

VL - 25

SP - 1870

EP - 1875

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -